Overview

David Aviezer was the President and CEO of Protalix BioTherapeutics for 12 years, during his tenure as CEO the company became public on wall street, gained FDA approval for its first drug, and signed a strategic agreement with Pfizer. In 2015 he stepped down from CEO position. Currently, he is Chairman of the boards of Metabomed, Kamari and FRONT Biopharma. David is an adjunct professor at Bar Ilan University's biotechnology department. Previously he was a board member of BIRAD and General Manager of ProChon Biotech. Prior to that, he was a visiting Scientist at Wyeth (now Pfizer) R&D in Pearl River, NY. He holds a Ph.D. from the Weizmann Institute in biochemistry and molecular biology of cancer and an MBA from Bar Ilan University.